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Summary
Background—Safety and efficacy have been shown in a phase 1 dose-escalation study involving 
a unilateral subretinal injection of a recombinant adeno-associated virus (AAV) vector containing 
the RPE65 gene (AAV2-hRPE65v2) in individuals with inherited retinal dystrophy caused by 
RPE65 mutations. This finding, along with the bilateral nature of the disease and intended use in 
treatment, prompted us to determine the safety of administration of AAV2-hRPE65v2 to the 
contralateral eye in patients enrolled in the phase 1 study.
Methods—In this follow-on phase 1 trial, one dose of AAV2-hRPE65v2 (1·5 × 1011 vector 
genomes) in a total volume of 300 μL was subretinally injected into the contralateral, previously 
uninjected, eyes of 11 children and adults (aged 11–46 years at second administration) with 
inherited retinal dystrophy caused by RPE65 mutations, 1·71–4·58 years after the initial subretinal 
injection. We assessed safety, immune response, retinal and visual function, functional vision, and 
activation of the visual cortex from baseline until 3 year follow-up, with observations ongoing. 
This study is registered with ClinicalTrials.gov, number NCT01208389.
Findings—No adverse events related to the AAV were reported, and those related to the 
procedure were mostly mild (dellen formation in three patients and cataracts in two). One patient 
developed bacterial endophthalmitis and was excluded from analyses. We noted improvements in 
efficacy outcomes in most patients without significant immunogenicity. Compared with baseline, 
pooled analysis of ten participants showed improvements in mean mobility and full-field light 
sensitivity in the injected eye by day 30 that persisted to year 3 (mobility p=0·0003, white light 
full-field sensitivity p<0·0001), but no significant change was seen in the previously injected eyes 
over the same time period (mobility p=0·7398, white light full-field sensitivity p=0·6709). 
Changes in visual acuity from baseline to year 3 were not significant in pooled analysis in the 
second eyes or the previously injected eyes (p>0·49 for all time-points compared with baseline).
Interpretation—To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy 
administered to the contralateral eye. The results highlight the use of several outcome measures 
and help to delineate the variables that contribute to maximal benefit from gene augmentation 
therapy in this disease.
Funding—Center for Cellular and Molecular Therapeutics at The Children’s Hospital of 
Philadelphia, Spark Therapeutics, US National Institutes of Health, Foundation Fighting 
Blindness, Institute for Translational Medicine and Therapeutics, Research to Prevent Blindness, 
Center for Advanced Retinal and Ocular Therapeutics, Mackall Foundation Trust, F M Kirby 
Foundation, and The Research Foundation—Flanders.
Introduction
Biallelic mutations in the RPE65 gene—which encodes all-trans retinyl ester isomerase, an 
enzyme crucial in the retinoid cycle—cause Leber’s congenital amaurosis type 2 and other 
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forms of severe retinal degenerative disease.1–4 Proof of principle of gene augmentation 
therapy with a recombinant adeno-associated virus (rAAV) for diseases caused by RPE65 
mutations was established in canine and murine models, and results from these studies5–8 
showed that the biochemical blockade of the visual cycle caused by RPE65 deficiency could 
be overcome. Clinical trials9–11 were initiated after additional efficacy, safety, and dosing 
studies were done in large animals.
Results from our phase 1 study10,12–14 at The Children’s Hospital of Philadelphia 
(Philadelphia, PA, USA) showed safe and stable improvement in retinal and visual function 
in all 12 patients. These individuals had been injected unilaterally and subretinally in their 
worseseeing, non-preferred eyes in a dose-escalation study with doses ranging from 1·5 × 
1010 to 1·5 × 1011 vector genomes of AAV2-hRPE65v2, an AAV vector carrying the wild-
type RPE65 cDNA.10,12 Most participants showed improved light sensitivity, increased 
navigational abilities, improved visual acuity, increased activation of the visual cortex, and 
evidence of improved function and structure of the visual pathways in their injected eye.15 
The patients also had an acquired afferent pupillary defect in the uninjected eye, suggesting 
that the injected (but not the uninjected) retina had been corrected by gene therapy.10,12–15
Research in context
Evidence before this study
On March 24, 2016, we searched PubMed for English language publications between Jan 
1, 1996, and Jan 1, 2016, using the following terms alone and in combination: “retina”, 
“gene therapy”, “AAV”, “adeno-associated virus”, “RPE65”, “clinical trial”, 
“readministration”, “two administrations”, “re-administration”, “vaccine”, and “immune 
response”. Several dose-escalation studies have tested gene augmentation therapy for 
retinal dystrophy caused by RPE65 mutations. Although improvements in various 
measures (visual acuity, visual fields, pupillary light reflex, full-field light sensitivity, and 
navigation) have been reported, none of the trials assessed the safety of administration of 
adeno-associated virus (AAV) vectors to the contralateral eye, even though RPE65 
mutations cause bilateral disease. Furthermore, the variables affecting improvements in 
retinal and visual function have not been clearly defined. Few, if any, successes have been 
reported after repeat administration of AAV vectors in human beings in any organ 
because of immune clearance. Thus, the safety and efficacy of a second administration 
need to be further tested.
Added value of this study
To our knowledge, our study is the first to successfully administer gene therapy to the 
contralateral eye. We showed that administration to the second eye is safe after previous 
exposure to AAV2-hRPE65v2 in individuals with RPE65 retinal disease, even in those 
with pre-existing immunity to AAV2. Repeat administration led to durable improvement 
in functional vision, retinal and visual function, and cortical responses. The ability to 
safely and effectively readminister AAV to the contralateral retina provides an 
opportunity to further increase visual function in individuals with vision impairment.
Implications of all the available evidence
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Our results support the conduct of phase 3 AAV2 gene therapy studies involving 
treatment of both eyes (using the reagent, dose, and volume in our study), as well as the 
use of several different outcome measures. The results also pave the way for cautious 
administration to the second eye in other ocular gene therapy studies, although in some 
contexts it might be advisable to maintain the untreated second eye as an internal control.
After the success of the unilateral injections, we hypothesised that functional vision and 
retinal and visual function could be further improved by delivering AAV2-hRPE65v2 to the 
contralateral, originally better-seeing eye. A chief concern was that humoral responses to 
AAV2 or the RPE65 protein generated after the initial AAV2 exposure could have prevented 
further benefit. More concerning, a cell-mediated immune response might cause 
inflammation and subsequent destruction of the terminally differentiated retinal cells, thus 
permanently removing any pre-existing vision. However, in experiments with large-animal 
models, repeat administrations resulted in efficacy with a high degree of safety.16 These 
encouraging pre-clinical results prompted us to do a follow-on study of the dose-escalation 
trial,12 in which we aimed to assess the safety of second-eye administration, determine 
whether retinal and visual function can be further improved after a unilateral injection, and 
delineate the variables affecting efficacy.
Methods
Patients
We invited 12 patients who had previously participated in the phase 1 dose-escalation 
study12 to take part in this follow-on phase 1 study. Enrolment criteria have been described 
elsewhere;17 briefly, we enrolled 11 of 12 patients from the original study. All surgery and 
follow-up tests were done at The Children’s Hospital of Philadelphia.
The clinical study had been reviewed and approved by the Institutional Review Board of and 
the Institutional Biological Safety Committee at The Children’s Hospital of Philadelphia 
(CHOP). All participants gave written informed consent or, in the case of children, assent or 
parental consent (appendix p 1).
Procedures
Patients received a subretinal administration of AAV2-hRPE65v2 (1·5 × 1011 viral genomes) 
to the contralateral, previously uninjected, eye (ie, the second eye) in a total subretinal 
volume of 300 μL;17 the procedure for subretinal injections has been described 
previously.18–20 The dose and volume corresponded to the highest dose assessed in the dose-
escalation study,12 which was well tolerated and resulted in improvement in several 
parameters of retinal and visual function.20 The targeted region for AAV delivery was the 
central superior retina or macula (figure 1), after verification of the presence of sufficient 
retinal cells through ophthalmoscopy, fundus photographs, and optical coherence 
tomography measurements. Surgical risks were lessened by introducing steps to minimise 
mechanical stress to the fovea.18
Patients were assessed at designated timepoints: at baseline (≤90 days before day 0 [day of 
surgical AAV delivery]) and on days 1, 3, 14, 30, 90, and 180, then once yearly during years 
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1–5. Adverse events and immune response were monitored, and efficacy data for all 
evaluable patients were analysed both individually and in a pooled manner. We used 
Goldmann (light-adapted) visual field tests to measure retinal and visual function, and full-
field light sensitivity threshold testing to measure sensitivity to light over a range greater 
than five log units. Rod photoreceptor sensitivity was measured through the use of white and 
blue stimuli, and cone photoreceptor sensitivity was measured through the use of red stimuli. 
Changes in visual acuity, measured with Holladay off-chart assignments21 in logarithm of 
the minimum angle of resolution (logMAR), were also monitored. Retinal-CNS pathways 
were assessed with a qualitative pupillary light reflex test, and functional vision was 
assessed with a mobility test.18–20 Mobility test videos were graded as pass or fail on the 
basis of predesignated weighting of accuracy and speed data; grading was done at an 
independent reading centre, and the readers were masked to study details, including 
treatment regimen (ie, which eye received the second administration) and light levels. 
Pupillary light reflex assessment was done by the study team, without prior masking of 
participant or visit details, from light-adapted (photopic) tests of alternating stimuli. 
Additionally, improvement in visual function was assessed by the change in activation in the 
visual cortex, measured with functional MRI (fMRI), in response to a contrast-reversing 
checkerboard stimuli, before and after subretinal injections. Acquisition and analyses of the 
fMRI data were done as a separate study, with separate consent and assent required, and 
involved eight participants in this study.17 Short-term results for three of these participants 
were previously reported.17 Additional details are provided in the appendix pp 6–8.
Statistical analysis
For eligible participants, we pooled data and assessed changes in the main efficacy outcomes 
(mobility testing and full-field light sensitivity) and an additional efficacy outcome (visual 
acuity) over time (ie, from baseline to day 30, day 90, day 180, year 1, year 2, and year 3) 
using mixed-effects linear regression models with random intercepts implemented via 
maximum likelihood. Results from these models were reported as changes with 95% CIs 
and corresponding p values. Stata 13.1 (Stata Corporation, College Station, TX) was used 
for statistical analyses, and the significance level was set at 0·05 for all tests. See appendix 
pp 6, 22 for full details. This study is registered with ClinicalTrials.gov, number 
NCT01208389.
Role of the funding source
The funders of the study (initially predominantly the Center for Cellular and Molecular 
Therapeutics at The Children’s Hospital of Philadelphia and then Spark Therapeutics) and 
personnel working for the funders were involved in study design, data collection, analysis, 
and interpretation, and writing of the report. None of the other funding sources had any 
direct role with respect to the design or execution of the study, data collection, analysis, and 
interpretation, or writing of the report. The corresponding author had full access to all data 
in the study and had final responsibility for the decision to submit for publication.
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Between Nov 18, 2010, and Oct 8, 2012, 11 of 12 patients in the original study received the 
injection. One patient (CH13) was not eligible for the follow-on intervention because of 
glaucoma in the second (ie, uninjected) eye. Bennett and colleagues17 have described the 6 
month results from the first three patients (all of whom were adults; table 1) to receive 
injection in the contralateral eye. Ten of 11 patients who received the intervention were 
included in the analysis (table 1). Results from NP04 were excluded in the analysis because 
he had culturepositive (Staphylococcus epidermidis) endophthalmitis after surgery. The 
diagnosis of bacterial endophthalmitis was made on the basis of recovery of pathogenic 
organisms from a vitreous sample obtained under aseptic conditions, an immediate response 
to the application of intravitreal antibiotics despite the discontinuation of systemic 
corticosteroids, and the absence of evidence for immunological response to the AAV2 capsid 
and RPE65 protein (appendix pp 2–4). Although we could not pinpoint the contamination 
with S epidermidis with absolute certainty, procedures were modified to minimise the 
chance of reoccurrence. Importantly, we have not seen this reaction in any of the other 22 
injected eyes in this and the dose-escalation study12 (including ten contralateral eyes, of 
which six received second administration after NP04 did; table 1) or in any of the 58 eyes 
receiving the same investigational agent at the same dose in a phase 3 study.18,19 In all 
evaluable patients, the left retina was injected, except for CH09, who had the right retina 
injected (figure 1).
No adverse events related to the AAV vector were observed. Adverse events related to the 
procedure were mostly mild and included dellen formation (ie, uneven surface of the cornea) 
adjacent to the suture in the early postoperative period in three patients (NP02, CH09, and 
CH10) and cataracts in two patients (CH06 and CH12). The dellens resolved with topical 
treatment, and the cataracts were successfully treated with standard cataract surgery. The 
treatment for bacterial endophthalmitis in NP04 led to elevated intraocular pressure and 
subsequent optic atrophy, which was the only serious adverse event attributed to 
participation in this trial. CH09 has severe myopia (requiring a correction of more than –10 
dioptres) and retinal thinning was noted after injection in the second eye. Compared with 
other patients, CH09 had lower macular volume and thinner fovea at baseline. In general, no 
changes in macular volume or retinal thickness were associated with the administration of 
AAV2-hRPE65v2, even when the injection area included the fovea (data not shown).
The humoral and cell-mediated responses to the AAV2 capsid and the RPE65 transgene 
were benign in all patients, with only one patient (CH10) developing a (low) positive cell-
mediated response to AAV at follow-up week 4 (appendix p 17). CH09 and NP04 had low 
positive results at baseline (ie, before vector injection), but not thereafter. Thus, the low 
positive responses at week 8 (CH10) and week 2 (CH09, NP04) did not occur in response to 
injection. CH10 had no inflammation, and the importance of this isolated event is unknown. 
Two individuals (CH06 and CH10) had high baseline neutralising antibodies to AAV2 
(appendix pp 11, 12, 18, 19) but no inflammation. Systemic exposure to the vector was 
limited (appendix pp 13, 20, 21). In summary, administration of AAV2-hRPE65v2 (1·5 × 
1011 viral genomes) to the contralateral retina appeared safe, irrespective of baseline 
immune status.
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Goldmann visual field tests at baseline revealed islands of responding retina, some without 
foveal fixation (figure 1). Visual fields of one patient (CH11) showed inter-test variability 
that was possibly caused by the perception of phosphenes,22 so that any changes resulting 
from the administration of AAV2-hRPE65v2 were difficult to interpret. In four patients 
(NP02, CH08, CH09, and CH10), qualitative analysis showed expansions of the visual field 
by day 30 that corresponded generally with the area of subretinal injection. In one 
participant (CH10), vision was restored in areas where large scotomas had been present. 
Total visual field area decreased in NP15 over time, but vision in the area generally 
corresponding to the injected region persisted over the 3 year period.
For all other outcomes, results for the second injected eye were compared with results over 
the same follow-up period for the first injected eye—ie, the eye studied in the dose-
escalation study;12 most patients received a lower dose to the first eye than to the second 
eye.
Results from full-field light sensitivity threshold testing show robust improvements in both 
rod and cone function by day 30 in the contralateral eyes, and improvements from baseline 
persisted until year 3 in pooled analyses (p<0·0001 for all timepoints; figure 2A–C; 
appendix pp 22–24). Eight of ten patients showed improvement in sensitivity (figures 3–5; 
table 2). In six patients (NP01, NP02, CH08, CH10, CH11, and NP15), sensitivity to white 
light increased by at least 10 dB in the second eye (CH08’s improvement was close to this 
level); smaller increases in sensitivity to white light were noted in two patients (NP03 and 
CH09; figures 3–5). Sensitivity to blue light increased by at least 10 dB for six patients 
(NP01, NP02, CH08, CH09, CH10, and NP15); smaller increases were noted in two patients 
(NP03 and CH11, figures 3–5). There was no change in sensitivity in CH06 or CH12 
(figures 4, 5). CH11 had a high degree of inter-test variability (possibly because of her 
perception of phosphenes22). Sensitivity to red light increased by more than 10 dB in the 
second eyes of three patients (NP01, NP02, and CH10) and by a smaller extent in five 
patients (NP03, CH08, CH09, CH11, and NP15). Sensitivity to red light increased in the 
initially injected eye of NP02, but the increase was not as much as that in the second eye. 
Improvements in rod photoreceptor responses (ie, responses to white and blue light) were 
larger than those in cone responses (ie, responses to red light; mean changes were white light 
17·9 dB [SD 1·33] vs blue light 17·6 dB [1·41] vs red light 10·8 dB [1·17]). No significant 
changes were seen in rod or cone function in the initially injected eyes during this study 
period (full-field sensitivity to white light p=0·6709, blue light p=0·3112, red light 
p=0·8277; figures 2A–C, 3–5; appendix pp 22–24). In two (NP01 and NP02) of three 
participants who had received low-dose AAV2-hRPE65v2 in their first eyes, large 
improvement was seen after second eye (high-dose) administration, and their first eyes had 
less robust responses (but improved compared with baseline function of their second eyes; 
figure 3), suggesting a dose-response effect.
Changes in visual acuity from baseline to year 3 were not significant in pooled analysis of 
logMAR scores in the second eyes or the previously injected eyes (p>0·49 for all timepoints 
compared with baseline; figure 2D; appendix pp 24–25). Changes were significant (change 
in logMAR ≥0·3 or a halving of the visual angle) in only two patients (CH12 and CH09). 
CH12 showed an improvement of 0·15–0·50 logMAR, depending on the off-chart 
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assignments used (appendix p 27).21,23 CH09 showed an initial decline in acuity that 
remained stable for the duration of follow-up; the deterioration in visual acuity was due to 
myopia-related macular thinning, exacerbated by subfoveal injection. Overall, changes in 
visual acuity were not associated with the involvement of the fovea in the subretinal 
injection.
Results of the mobility test showed an improvement in the second eyes by day 30 
(p=0·0011) that persisted through year 3 (p=0·0002 compared with baseline; figures 2E and 
6; appendix p 22) with observation ongoing, suggesting that patients could complete the 
mobility test more accurately and quickly under lower illuminances than at baseline. No 
significant difference was seen in mobility between baseline of the follow-on study and post-
intervention timepoints in the previously injected eye (p=0·7398). Most patients had 
improved mobility after administration to the contralateral eye (figure 6), with the exception 
of CH06 and CH12, who showed no change in mobility.
After administration to the second eye, qualitative assessment of pupillary light reflex shows 
improvement lasting for at least 3 years in all patients (appendix pp 27–28). Whereas the 
responses were maintained in the initially injected eye, the responses of the second injected 
eyes, which all received the maximal dose, were generally more robust. For example, before 
administration to the second eye, CH09 had strong pupillary light reflexes after stimulus of 
the left (first injected) eye. After injection to the right retina in the follow-on study, 
additional strong responses were seen in this eye after illumination.
Overall comparison of fMRI results at baseline and at 1 year post-administration showed 
significant widespread bilateral activation in all areas of the visual cortex, extending from 
medial to lateral and posterior to anterior aspects of the occipital cortex (figure 7). The 
pattern of activation varied for each individual depending on their age, extent of disease 
progression, or other factors (eg, chronic smoking, which is known to abate cortical blood 
flow and thus the fMRI signal). NP01 had lower cortical activation than other patients, 
which might be attributable to her being a chronic smoker. In all eight patients who 
underwent neuroimaging, cortical activation in response to the high-contrast stimuli 
increased, and responses to medium-contrast and low-contrast stimuli also increased, albeit 
to a smaller extent. See appendix pp 6–8 for longitudinal analysis.
In summary, delivery of AAV2-hRPE65v2 to the second eye resulted in long-term 
improvements in multiple measures of rod photoreceptor function and also a measure of 
cone photoreceptor function in most participants (table 2).
Discussion
Subretinal administration of AAV2-hRPE65v2 to the contralateral eye showed a high degree 
of safety and stable, persistent improvement (for at least 3 years, with observation ongoing) 
in retinal and visual function and functional vision in most patients. Parallel improvement in 
visual cortex responses was seen in all eight individuals who participated in fMRI studies. 
Improvement in subjective and objective measures of retinal and visual function was 
observed as early as day 30.
Bennett et al. Page 8













Similar to results from animal studies, participants in our study showed strong and stable 
improvements in light sensitivity after contralateral-eye administration of AAV2-hRPE65v2, 
even those with pre-existing systemic antibodies to the AAV2 capsid or the transgenic 
RPE65 protein. With this particular vector preparation, high-dose AAV2-hRPE65v2 can be 
safely administered to the subretinal space of the second eye, with evidence of efficacy. 
Furthermore, no inflammatory response was reported in either eye, and the measured 
immunological responses were benign.
Previously, following administration of AAV2-hRPE65v2, we noted a strong bias towards 
improvement in the short-wavelength (ie, blue) spectrum, which is consistent with an 
improvement in rod photoreceptors.17 This is analogous to the Purkinje phenomenon, which 
occurs during dark adaptation in which the peak sensitivity of the retina shifts from the red 
(cone) to the blue (rod) photoreceptor population.24 Of note, after administration to the 
contralateral retina, eight of ten patients had robust and stable improvement in both cone and 
rod photoreceptor responses; the macula (or a portion thereof) of these patients had been 
exposed to AAV2-hRPE65v2. The improvement in cone function in most patients suggests 
that the chromophore generated by the RPE65 isomerase, made from the RPE65 transgene, 
might activate cone photoreceptors in addition to rod photoreceptors.
The results of our study help to define clinical variables and procedures that might affect the 
magnitude of the outcome. Because RPE65 mutations cause degenerative disease, early 
intervention is expected to lead to greater potential gain. However, if the number of 
remaining photoreceptors is sufficient, even patients in the third or fourth decades of life (eg, 
NP02) could benefit substantially. One young adult (CH06) did not show improvement, 
possibly because of her history of encephalitis and inner retinal abnormalities caused by 
optic nerve drusen. CH06 had high-titre neutralising antibodies to AAV2 at baseline; 
however, another patient (CH10) with high-titre neutralising antibodies did benefit from 
administration to the second eye. Although CH06 has two disease-causing RPE65 
mutations, her heterozygous RDH12 mutation might have also affected her outcome. 
Finally, although retinal thinning associated with high myopia does not prevent benefit (as 
seen in CH09), this effect might make the macula more vulnerable to mechanical stress 
during subretinal injection. The risk to pathological myopes might be minimised by limiting 
the volume of vector injected or by avoiding delivery of the vector in the foveal area.
Six phase 1 dose-escalation trials of interventions targeting RPE65-mediated retinal disease 
have been initiated, three of which have reported on results from the full set of 
participants.12,25,26 The vectors used in the trials differed in several crucial parameters, 
including the method of purification, presence of elements that can affect the level of 
expression, and composition of the excipient.9–12 Two of the trials used constitutive 
promoters;10,11 the third used a weaker promoter that is active only in the retinal pigment 
epithelium.9 Major differences in surgical approaches included delivery volume, regions of 
retina targeted, and perioperative regimens of steroid use; the ages of the participants and the 
extent of photoreceptor degeneration also differed. Differences also existed in outcome 
measures and their analyses.12,25,26 Nevertheless, all three trials showed a high level of 
safety and improvement of retinal and visual function, as determined by increased light 
sensitivity and other parameters.10–12,26,27 Two of the groups used mobility tests in all 
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cohorts to assess participants’ improved abilities to navigate under dim lighting.9,10,12,26 
Most participants tested had additional improvements in pupillary light reflexes10,12 and 
visual cortex responses,14,15 and in dark-adapted perimetry, microperimetry,9 and visual 
acuity.10,12 Jacobson and colleagues,28 reporting on three of 15 participants in their trial, 
described a decrease in light sensitivity after 3 years, although the long-term sensitivity after 
unilateral injection remained significantly higher than that at baseline. Another concern was 
that the degenerative process continued, although improvements in visual function again 
persisted.29 Bainbridge and colleagues26 also reported a decrease in sensitivity in six of 12 
participants after 6–12 months; however, the initial level of improve ment was not as high as 
that reported in other studies, perhaps because the weaker RPE-specific promoter was used. 
Further, the surgical details in this trial9 differed substantially from those in the other trials.
One question that remains relates to the durability of the functional benefit of a one-time 
injection. Cideciyan and colleagues29 have focused on statistical analyses of retinal 
thickness of participants of gene therapy clinical trials in comparison to that in a normative 
(so-called natural history) database, but this database might not account for variables that 
would affect retinal thickness, such as the area of injection or ageing. Jacobson and 
colleagues28 have also focused on measures from microperimetry in the injected eyes of 
three of 15 individuals receiving different doses and volumes of vector and in different 
retinal locations. Of note, fundamental differences existed in the various trials, including 
vector design and purification, use of surfactant, systemic immunomodulation, dosing, 
surgical delivery, and outcome measures used to assess treatment effect. Therefore, to make 
generalisations from results of all the studies is problematic. Importantly, our study included 
a clinically meaningful outcome measure—ie, mobility—and has shown durable positive 
results across multiple measures, with observation ongoing. A second administration to the 
previously uninjected eye—with the same dose, volume, and general target location in the 
retina—clearly results in reproducible, large, and persistent improvements in retinal and 
visual function and in functional vision that is important for vision-dependent activities of 
daily living. A limitation of our study is that the initially injected eyes were the worse-seeing 
eyes, which had received different doses previously in the dose-escalation study. 
Nonetheless, it is now possible to study the durability of effect in a more controlled manner
—namely, in a large, randomised controlled phase 3 study (NCT00999609). In this ongoing 
study, both eyes received the same dose and volume of AAV-hRPE65v2 near simultaneously, 
which will enable the identification of additional variables affecting outcomes.
In summary, this report is the first to show long-term improved functional vision and retinal 
and visual function after repeat gene therapy administration. Efficacy after repeat 
administration of AAVs in human beings has been described in only one other clinical 
trial,30 which used AAV to produce an immune response to vaccinate against HIV.30 The 
immune-privileged nature of the target tissue is likely to contribute to the strong safety 
profile of AAV2-hRPE65v2. Other features also contribute to the safety of the 
administration to the second eye of this particular vector—eg, the relatively low dose of a 
vector that is largely devoid of empty capsids, thereby resulting in a low antigen load.
Following a second administration of this vector, eight of ten participants included in the 
analysis can now navigate under dimmer lighting conditions with their second injected eyes. 
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This clinically meaningful test of functional vision was corroborated by additional measures 
of retinal sensitivity.
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Figure 1. Subretinal areas of second-eye injection and Goldmann visual fields
Scotomas and the natural blind spot are shown in black.
Bennett et al. Page 13













Figure 2. FST with (A) white, (B) blue, and (C) red stimuli, (D) visual acuity measurements, and 
(E) mobility change score
(A–C) Note that the scales of the y axes are different. The more negative the threshold, the 
higher the sensitivity. (D) Visual acuity measurements are shown as mean logMAR scores 
for each visit. (E) The mobility change score reflects the change in the ability of the patients 
to pass the mobility test under lower illuminance than at baseline. Error bars represent 1 SE. 
Only significant p values (ie, p<0·05) are shown. See appendix p 6 for detailed statistical 
analyses. FST=full-field light sensitivity thresholds.
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Full-field light sensitivity threshold results immediately before and after administration of 
AAV2-hRPE65v2 to the second, contralateral eye in patients given low-dose treatment in 
their first eye
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Full-field light sensitivity threshold results immediately before and after administration of 
AAV2-hRPE65v2 to the second, contralateral eye in patients given medium-dose treatment 
in their first eye
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Full-field light sensitivity threshold results immediately before and after administration of 
AAV2-hRPE65v2 to the second, contralateral eye in patients given high-dose treatment in 
their first eye
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Figure 6. Change in mobility score
Participants are listed according to their original dose assignment when the first eye was 
injected: (A) low dose, (B) medium dose, and (C) high dose. A positive change score 
reflects the ability to navigate more accurately and quickly at dimmer light levels than at 
baseline. See appendix p 6 for detailed statistical analyses. *Mobility testing for NP01, 
CH11, and CH12 was not standardised until their follow-on visits in year 1. All other 
participants began the follow-on study after mobility testing standardisation.
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Figure 7. fMRI results at baseline of the follow-on study and at 1 year after administration to the 
second eye
Participants are listed according to their original dose assignment when the first eye was 
injected: (A) low dose, (B) medium dose, and (C) high dose. Significant areas of cortical 
activations are shown as orange clusters overlaid onto the medial and lateral representations 
of the inflated cortex. Results are presented for the left eye for all but one participant 
(CH09), who received administration to his right eye in the follow-on study. For follow-up 
fMRI results, a stringent statistical threshold of false discovery rate <5%, corrected p<0·004, 
and continuous cluster area ≥100 mm2 was used for all patients (except NP01).14,17 For 
baseline fMRI results, a relaxed threshold of uncorrected p<0·05 and continuous cluster area 
≥50 was used for all patients (except NP15 and NP02) to reveal cortical activations.
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